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Abstract
Three studies report estimates of the cost and effectiveness of alternate strategies for screening
the average-risk Australian population for colorectal cancer. The options considered are faecal
occult blood testing, double contrast barium enema, sigmoidoscopy and colonoscopy. At present,
there is no consensus over which screening method is optimal by the economic criterion. Also, the
existing studies report a mixture of average and incremental cost-effectiveness ratios derived from
data collected between 1994 and 2002. We suggest average cost-effectiveness ratios are not useful
for decision-making and illustrate how they differ from the preferred incremental cost-effectiveness
ratio. We then update the cost data reported in the three studies to 2002 prices and calculate
incremental cost-effectiveness ratios where not previously available. Our re-analysis of one study
contradicts the conclusions drawn by the authors, who had only calculated average cost-
effectiveness ratios. In particular, we find their recommendation of population screening with
colonoscopy would cause, annually, between 33 and 1,322 years of life to be lost and between
$M17 and $M87 to be wasted. Based on updated cost data and the incremental analysis, our
findings indicate that population screening using biennial faecal occult blood testing ($39,459 per
life-year gained), annual faecal occult blood testing ($30,556 per life-year gained) and colonoscopy
($26,587 per life-year gained) are cost-effective. Hence, the decision over which method of
screening is optimal remains ambiguous across the three studies. We recommend policy-makers
choose the study they believe produces the most accurate estimates of cost and health effect,
identify their willingness to pay for health benefits and consider other issues relevant to the
decision.
Introduction
In 1996, Salkeld et al. [1] found that screening the aver-
age-risk Australian population for colorectal cancer using
a faecal occult blood test (FOBT), compared to existing
practice, would cost $24,660 per life-year gained (LYG).
Due to uncertainty regarding the effectiveness of FOBT
screening, they report a range of values, between $12,695
and $67,848 per LYG. Randomised controlled trials of
population screening with FOBT conducted in the UK [2]
and Denmark [3], but published after Salkeld et al.'s
study, have reduced this uncertainty. The cost-effective-
ness analyses based on the UK trial data [4] suggest a cost
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mately $AU3,370–13,974) and the analysis of the Danish
trial data [5] suggest a cost per life-year gained between
17,000–42,000DKK (approximately $AU3,916–9,672).
Three years before publication of Salkeld's study Bolin [6]
discussed the advantages of using colonoscopy for popu-
lation screening, and in 1996, he suggested colonoscopy
was cost-effective [7]. In 1997, he asked whether the time
had come to use colonoscopy for population screening in
Australia [8]. Kermond [9] responded suggesting double
contrast barium enema (DCBE) should not be overlooked
arguing colonoscopy is 10 times more expensive, false
negatives still occur and complication rates are higher.
Bolin argued, in the same issue of the MJA, that the sensi-
tivity of colonoscopy exceeds DCBE, the complication rate
is only 0.1% and cost differentials are actually less than
those suggested by Kermond [9].
Bolin also claimed that FOBT at one and three years and
colonoscopy at 10 years, assuming a 10-year period dur-
ing which time the cancer is detectable and curable
(known as the dwell time), are cost-effective modes of
CRC screening, probably referring to data subsequently
published in 1999 [10]. For this research, the authors sub-
stituted Australian values for cost parameters into a US
model of the cost-effectiveness of CRC screening [11] and
generalised the results to the Australian population. They
reported change in cost and change in life-years gained, as
compared to existing practice, for competing screening
strategies that encompass FOBT, colonoscopy, flexible sig-
moidoscopy and DCBE [10]. By assuming that society is
willing to pay up to $US40,000 (approximately
$AU65,449 in 2002 prices) per LYG, Bolin proposed that
annual FOBT, triennial FOBT, triennial DCBE, five-yearly
DCBE, five-yearly colonoscopy and ten-yearly colonos-
copy are all cost-effective and concluded that physicians
have the option of offering individuals a range of screen-
ing alternatives, including colonoscopy [10]. Since pub-
lishing the research Bolin has argued, on four separate
occasions that population screening with colonoscopy is
cost-effective [12-15]. The last of these, in 2002 [14], pro-
voked Macrae and Hebbard [16] to criticise Bolin's inter-
pretation of epidemiological data.
In 2004, O'Leary et al. [17] also addressed the economic
questions around population screening in Australia. They
estimated the cost-effectiveness, compared to existing
practice, of FOBT, flexible sigmoidoscopy and colonos-
copy, and found flexible sigmoidoscopy and colonoscopy
were cost-effective but FOBT was not.
There are important differences in the way that Salkeld et
al. [1], Bolin et al. [10] and O'Leary et al. [17] report the
Australian cost and effectiveness data. Salkeld et al.
reports an incremental cost-effectiveness ratio, O'Leary et
al. reports both average and incremental cost-effectiveness
ratios, however they draw their conclusions from an aver-
age analysis. Bolin only calculates average cost-effective-
ness ratios. The correct ratio for decision-making is an
incremental cost-effectiveness ratio: McMahon [18]
argues the use of average ratios is not meaningful; Drum-
mond [19] and Gold [20] both discuss why incremental
rather than average cost-effectiveness ratios are relevant
for decision making; and, both Torgerson [21] and Neu-
hauser & Lewicki [22] provide examples of how average
analyses muddy the waters. In their much-cited 1975
paper, Neuhauser & Lewicki [22] reviewed data on screen-
ing for CRC. They illustrated that repeatedly testing a stool
sample up to six times, when a previous test result was
negative, would capture all cases of CRC, at an average
cost per case of $2451. They also did an incremental anal-
ysis, with the same data, and showed the incremental cost
per case detected, from the fifth to sixth round of testing
was $47 million. This illustrates that average analyses can
be grossly misleading.
We have four objectives in this paper: first, to demonstrate
why incremental, not average, cost-effectiveness ratios
should be used for decision-making; second, to update
the cost data reported by Salkeld et al. [1], Bolin et al. [10]
and O'Leary et al. [17] to 2002 Australian dollar prices;
third, to calculate incremental cost-effectiveness ratios
from the Bolin data; and fourth, to discuss the results of
our re-analysis, comparing the outcomes from the three
previous studies. This will provide readers with an up-to-
date and appropriate assessment of the existing cost-effec-
tiveness data for population-based CRC screening pro-
grammes in Australia.
Defining average & incremental cost-
effectiveness ratios
Average cost-effectiveness ratios for health care interven-
tions are the amounts by which costs change from a base-
line comparator (∆C) divided by the amount by which
health benefits change from a baseline comparator (∆E).
The baseline comparator is often existing practice. We
illustrate this method with hypothetical data in Table 1 by
presenting the change in costs and health effects that arise
from four competing health care alternatives. If we remain
with Existing Practice, there is no change in cost or health
effect. However, if we are committed to generating health
effects and we wish to be efficient, then we should choose
the cheapest option that improves health outcomes. The
data in Table 1 show that Intervention 4 generates the best
ratio of (∆C) and (∆E) when compared to Existing Prac-
tice. Cost changes by $145,000 and health effects change
by 150 and the cost per LYG is $967.Page 2 of 9
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1 (which is a graph of the data in Table 1). Intervention 1
generates less health benefit and higher costs than Inter-
vention 4, a situation described as 'simple dominance'.
For this comparison, Intervention 4 is preferred on both
costs and outcomes. Intervention 2 also generates less
health effect but differs from Intervention 1 in that it's
cheaper than Intervention 4; however, the cost per LYG
from Intervention 2 is greater than the cost per LYG from
Intervention 4. This situation is known as 'extended dom-
inance' and is only relevant if the cost of Intervention 4
($145,000) exceeds the total amount of money available
to the decision-maker. Rather than choosing Intervention
2 over Intervention 4, it would be better (more produc-
tively efficient) to choose some blend of existing practice
and Intervention 4. This implies that some proportion of
the population would receive Intervention 4 and the
remainder would receive existing practice. This raises
questions of equity of access and so poses another set of
problems for decision-makers. If the available budget
exceeds $145,000, there is a further question to consider.
Do we invest in the more costly but more effective Inter-
vention 3? Some care is required when making this deci-
sion. The average cost-effectiveness ratio for Intervention
3 ($1,200 per LYG), represented by the dashed line on Fig-
ure 1, is misleading. It's calculated by comparing Interven-
tion 3 to existing practice; yet, the relevant decision is
whether we should invest in Intervention 3 given that we
have established Intervention 4 as the most cost-effective
option. We must consider the incremental changes in cost
and health effects compared to the next best alternative,
Intervention 4. The incremental cost-effectiveness ratios
for Interventions 4 and 3 are marked with solid lines on
Figure 1. When a more effective alternative also costs
more, then the decision-maker must compare the
increased cost with the increased effects [19]. The only
way to achieve this is to conduct an incremental analysis,
which we illustrate in Table 2. Investing in Intervention 3,
as compared to 4, changes total costs by $155,000 and
LYG by 100, yielding an incremental cost-effectiveness
ratio of $1,550 per LYG not the $1,200 per LYG as previ-
ously estimated using average cost-effectiveness ratios and
illustrated in Table 1.
Imagine you have decided to take a holiday in a beach
resort. You face a decision between a standard apartment
for $1,000 and a Penthouse apartment for $1,300.
Because you have decided to take the holiday (and so one
of the apartments), it is the difference in cost ($300) that
you compare to the difference in benefit (penthouse vs.
standard apartment). If you don't perceive the additional
benefit to be worth the extra $300, then you reject the
penthouse. This simple example illustrates the impor-
tance of thinking about decisions in terms of incremental
changes. An average analysis with both options compared
to 'no holiday' may lead to a bad decision.
Table 1: An illustration of average cost-effectiveness ratios for four competing hypothetical health care interventions
Change in cost ($) Change in health effect (Life-years Gained) Average cost-effectiveness ($)
(∆C) (∆E) (∆C) divided by (∆E)
Existing Practice 0 0
Intervention 1 200,000 12 16,667
Intervention 2 75,000 15 5,000
Intervention 3 300,000 250 1,200
Intervention 4 145,000 150 967
Table 2: An illustration of average and incremental cost-effectiveness ratios for the two remaining hypothetical health care 
interventions
Intervention Cost ($) Incremental 
changes in cost ($)
Effectiveness 
(LYG)
Incremental changes in 
effectiveness (LYG)
Average cost-
effectiveness ratio ($)
Incremental cost-
effectiveness ratio ($)
(a) (b) (c) (d) (a)/(c) (b)/(d)
Existing Practice 0 0
Intervention 4 145,000 145,000 150 150 967 967
Intervention 3 300,000 155,000 250 100 1,200 1,550
Note: Interventions 1 and 2 have been rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussionPage 3 of 9
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We converted Bolin's $US dollar estimates to Australian
dollars with the exchange rate reported in the original arti-
cle [10] and adjusted the estimates reported by Bolin,
Salkeld and O'Leary to 2002 prices using a health price
index [23]. As Salkeld and O'Leary reported incremental
cost-effectiveness ratios, we only need to calculate incre-
mental cost-effectiveness ratios from the Bolin data. We
achieved this by inputting the reported estimates of (∆C)
and (∆E) into decision analysis software [24]. Assuming a
5-year dwell time (the period during which cancer can be
detected and cured), we include 13 screening strategies
and the existing practice comparator. For a 10-year dwell
time, estimates of (∆C) and (∆E)were reported for differ-
ent, additional, frequencies of FOBT, flexible sigmoidos-
copy and DCBE screening, resulting in 27 strategies and
the existing practice comparator. We ranked all strategies
by increasing cost, estimated incremental cost and effec-
tiveness, and excluded all strategies for which other
options prevailed on the basis of 'simple' or 'extended'
dominance. Finally, we reported the strategies not
excluded due to either 'simple' or 'extended' dominance
and present the relevant incremental cost-effectiveness
ratios.
In Table 3, we describe all strategies evaluated by the
authors of the three studies.
In Figure 2, we illustrate the costs and effects of all strate-
gies reported by Bolin, assuming a 5-year dwell time. The
strategies to the left and above the cost-effective frontier,
defined by the solid line, are excluded by either 'simple' or
'extended' dominance. The three remaining (un-domi-
nated) strategies, that define the cost-effective frontier, are
EXISTING PRACTICE, DCBE3 and FOBT1+DBCE3. In
Table 4, we report all corresponding costs, health benefits
and cost-effectiveness ratios, and indicate the options that
are 'simply' dominated. In Table 5, we report the incre-
mental cost-effectiveness ratios for the options that sur-
Change in cost and change in effect from four hypothetical health care interventionsFigur 1
Change in cost and change in effect from four hypothetical health care interventions.
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options define the cost-effective frontier.
In Figure 3, we illustrate the costs and effects for all strate-
gies reported by Bolin, assuming a 10-year dwell time. In
this case EXISTING PRACTICE, FOBT2, DCBE5, DCBE3,
FOBT1+DCBE5 and FOBT1+DCBE3 define the cost-effec-
tive frontier. In Table 6, we report all corresponding costs,
health benefits and cost-effectiveness ratios, and indicate
the options that are 'simply' dominated. In Table 7, we
report the incremental cost-effectiveness ratios for the
options that survive the tests of 'simple' or 'extended'
dominance; again, these options define the cost-effective
frontier.
The incremental cost-effectiveness ratio derived from the
Salkeld data, in 2002 prices, for FOBT, is $30,556 per
LYG, and the 2002 incremental cost-effectiveness ratios
from the O'Leary data are $17,356 per LYG for FSIG and
$26,587 per LYG for COL.
These results define the screening options that are pre-
ferred (ie, not dominated), by the measure of cost-effec-
tiveness, for population-based CRC screening in Australia.
However, the decision over which to choose depends on
additional factors that we discuss next.
Discussion
We defined average and incremental cost-effectiveness
ratios and emphasise the latter are relevant for decision-
making. We calculated incremental cost-effectiveness
ratios, in 2002 prices, for a number of population screen-
ing strategies, for which Bolin had previously reported
average cost-effectiveness ratios. For Bolin's estimates of
(∆C) and (∆E), for a 5-year dwell time, we found only
DCBE3 ($49,792 per LYG) and FOBT1+DCBE3
Table 3: Descriptions of the screening strategies included in the re-analysis
Screening strategy Description of screening strategy Salkeld [1] Bolin [10]
(5-year dwell time)
Bolin [10]
(10-year dwell time)
O'Leary [17]
Existing practice Existing screening practices X X X
COL10 10-yearly colonoscopy X X X
COL5 5-yearly colonoscopy X X
COL one off screening colonoscopy at age 50 X X
DCBE one off double contrast barium enema X
DCBE10 10-yearly double contrast barium enema X
DCBE15 15-yearly double contrast barium enema X
DCBE20 20-yearly double contrast barium enema X
DCBE3 3-yearly double contrast barium enema X X
DCBE5 5-yearly double contrast barium enema X X
FOBT10 10-yearly faecal occult blood test X
FOBT15 15-yearly faecal occult blood test X
FOBT2 2-yearly faecal occult blood test X X
FOBT20 20-yearly faecal occult blood test X
FOBT5 5-yearly faecal occult blood test X
FOBT one off faecal occult blood test X
FOBT1 annual faecal occult blood test X X X X
FOBT1+DCBE3 annual faecal occult blood test and 3-yearly double 
contrast barium enema
X X
FOBT1+DCBE5 annual faecal occult blood test and 5-yearly double 
contrast barium enema
X X
FOBT1+FSIG3 annual faecal occult blood test and 3-yearly flexible 
sigmoidoscopy
X X
FOBT1+FSIG5 annual faecal occult blood test and 5-yearly flexible 
sigmoidoscopy
X X
FOBT3 3-yearly faecal occult blood test X X
FSIG flexible sigmoidoscopy once only X
FSIG10 10-yearly flexible sigmoidoscopy X X
FSIG15 15-yearly flexible sigmoidoscopy X
FSIG20 20-yearly flexible sigmoidoscopy X
FSIG3 3-yearly flexible sigmoidoscopy X X
FSIG5 5-yearly flexible sigmoidoscopy X XPage 5 of 9
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Updated costs and effects for Bolin et al's 13 tested strategies, assuming a five-year dwell time.
Table 4: Estimates of costs in 2002 prices, health benefits and cost-effectiveness from Bolin et al. [10], assuming a five-year dwell time
Strategy Cost ($) Incremental 
changes in cost ($)
Effectiveness 
(LYG)
Incremental 
changes in 
effectiveness 
(LYG)
Average cost-
effectiveness ratio ($)
Incremental cost-
effectiveness ratio ($)
(a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING 
PRACTICE
0 0 (Undefined)
FOBT3 109,167,314 109,167,314 2,010 2,010 54,312 54,312
COL 195,987,062 86,819,748 1,166 -844 168,085 (Simply Dominated)
FSIG5 205,570,434 96,403,120 3,365 1,355 61,091 71,146
FOBT1 230,156,355 24,585,921 4,447 1,082 51,755 22,723
DCBE5 253,881,621 23,725,266 5,050 603 50,274 39,345
FSIG3 271,052,169 17,170,548 3,909 -1,141 69,341 (Simply Dominated)
COL10 278,701,522 24,819,901 3,718 -1,332 74,960 (Simply Dominated)
DCBE3 307,911,416 54,029,795 6,184 1,134 49,792 47,645
COL5 360,264,079 52,352,663 6,181 -3 58,286 (Simply Dominated)
FOBT1+FSIG5 364,595,167 56,683,751 5,849 -335 62,335 (Simply Dominated)
FOBT1+DCBE5 373,803,843 65,892,427 6,573 389 56,870 169,389
FOBT1+FSIG3 420,786,416 46,982,573 6,032 -541 69,759 (Simply Dominated)
FOBT1+DBCE3 424,911,339 51,107,496 7,020 447 60,529 114,334
DCBE3
FOBT1+
DCBE3
Existing
PracticePage 6 of 9
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assuming a five-year dwell time
Strategy Cost ($) Incremental 
changes in cost ($)
Effectiveness 
(LYG)
Incremental 
changes in 
effectiveness 
(LYG)
Average cost-
effectiveness ratio ($)
Incremental cost-
effectiveness ratio ($)
(a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING 
PRACTICE
0 0 (Undefined)
DCBE3 307,911,416 307,911,416 6,184 6,184 49,792 49,792
FOBT1+DBCE3 424,911,339 116,999,923 7,020 836 60,529 139,952
Note: Other options rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussion.
Table 6: Estimates of costs in 2002 prices, health benefits and cost-effectiveness from Bolin et al. [10], assuming a 10-year dwell time
Strategy Cost ($) Incremental 
changes in cost ($)
Effectiveness 
(LYG)
Incremental 
changes in 
effectiveness 
(LYG)
Average cost-
effectiveness ratio ($)
Incremental cost-
effectiveness ratio ($)
(a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING 
PRACTICE
0 0 (Undefined)
FOBT 24,429,089 24,429,089 352 352 69,401 69,401
FOBT20 31,633,953 7,204,864 558 206 56,692 34,975
FOBT15 37,620,230 5,986,277 681 123 55,243 48,669
FOBT10 47,472,852 9,852,622 951 270 49,919 36,491
FOBT5 75,561,379 28,088,527 1,674 723 45,138 38,850
FSIG 102,900,905 27,339,526 1,222 -452 84,207 (Simply Dominated)
FOBT3 105,521,804 29,960,425 2,605 931 40,507 32,181
FSIG20 120,362,301 14,840,497 1,892 -713 63,616 (Simply Dominated)
FSIG15 131,780,307 26,258,503 2,294 -311 57,446 (Simply Dominated)
DCBE 134,697,657 29,175,853 1,896 -709 71,043 (Simply Dominated)
FOBT2 140,117,791 34,595,987 3,551 946 39,459 36,571
FSIG10 148,850,170 8,732,379 3,127 -424 47,602 (Simply Dominated)
DCBE20 158,390,199 18,272,408 2,939 -612 53,893 (Simply Dominated)
DCBE15 173,448,383 33,330,592 3,566 15 48,639 2,222,039
COL 190,862,405 17,414,022 2,368 -1,198 80,601 (Simply Dominated)
DCBE10 194,089,298 20,640,915 4,778 1,212 40,621 17,030
FSIG5 204,328,539 10,239,241 3,583 -1,195 57,027 (Simply Dominated)
FOBT1 224,367,390 30,278,092 5,271 493 42,566 61,416
DCBE5 248,112,291 23,744,901 6,023 752 41,194 31,576
COL10 265,297,565 17,185,274 5,970 -53 44,438 (Simply Dominated)
FSIG3 270,484,399 22,372,108 3,993 -2,030 67,740 (Simply Dominated)
DCBE3 304,301,903 56,189,612 6,720 697 45,283 80,616
COL5 357,822,831 53,520,928 6,583 -137 54,356 (Simply Dominated)
FOBT1+FSIG5 361,026,560 56,724,657 6,344 -376 56,908 (Simply Dominated)
FOBT1+DCBE5 370,181,240 65,879,337 7,076 356 52,315 185,054
FOBT1+FSIG3 417,677,588 47,496,348 6,457 -619 64,686 (Simply Dominated)
FOBT1+DCBE3 422,777,702 52,596,462 7,299 223 57,923 235,859Page 7 of 9
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assuming a 10-year dwell time
Strategy Cost ($) Incremental 
changes in cost ($)
Effectiveness 
(LYG)
Incremental 
changes in 
effectiveness 
(LYG)
Average cost-
effectiveness ratio ($)
Incremental cost-
effectiveness ratio ($)
(a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING 
PRACTICE
0 0 (Undefined)
FOBT2 140,117,791 140,117,791 3,551 3,551 39,459 39,459
DCBE5 248,112,291 107,994,500 6,023 2,472 41,194 43,687
DCBE3 304,301,903 56,189,612 6,720 697 45,283 80,616
FOBT1+DCBE5 370,181,240 65,879,337 7,076 356 52,315 185,054
FOBT1+DCBE3 422,777,702 52,596,462 7,299 223 57,923 235,859
Note: Other options rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussion
Updated costs and effects for Bolin et al's 27 tested strategies, assuming a ten-year dwell timeFigur  3
Updated costs and effects for Bolin et al's 27 tested strategies, assuming a ten-year dwell time.
DCBE5
FOBT1+
DCBE5
Existing
Practice
FOBT2
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a 10-year dwell time, FOBT2 ($39,459 per LYG), DCBE5
($43,687 per LYG), DCBE3 ($80,616 per LYG),
FOBT1+DCBE5 ($185,054 per LYG) and FOBT1+DCBE3
($235,859 per LYG) were preferred (not dominated).
Incremental cost-effectiveness ratios are useful for deci-
sion-making when a ceiling value for a LYG is specified.
Bolin argued in 1996 [7] that $US40,000 per LYG was the
relevant cut-off (approximately $AU65,449 in 2002
prices). We prefer a decision rule described by Garber &
Phelps [25] that states a LYG is worth approximately twice
the median annual per capita income. They derived this
value from a model of optimal lifetime spending for med-
ical care and explored its relationship to the cost-effective-
ness criterion. They evaluated the model in terms of
maximizing utility for individuals, with utility a function
of income and health. Their rule implies, for Australia, a
rational cut-off for one LYG is approximately $AU39,000
[26].
If we apply this rule to our interpretation of Bolin's data,
we wouldn't recommend any additional population
screening activities for the 5-year dwell time, and for a 10-
year dwell time, we would only recommend FOBT2.
Based on the O'Leary and Salkeld data we recommend
COL and FOBT1, respectively. The results in Tables 4 and
6 illustrate the colonoscopy strategies, championed by
Bolin, would cause between 33 and 1,322 years of life to
be lost and between $M17 and $M87 to be wasted. We
showed that all colonoscopy options were dominated by
more cost-effective alternatives.
Despite our re-analysis, the decision over which model of
CRC screening is optimal for the Australian, average-risk
population remains ambiguous. While the incremental
cost-effectiveness ratios from two studies support annual
FOBT [1] or biennial FOBT [10], the most recent study
supports colonoscopy [17]. At least we now have
incremental cost-effectiveness ratios in 2002 prices. While
two of the studies agree that FOBT screening is preferred,
we have not investigated why the O'Leary [17] analysis
leads to a different conclusion. The answer may be sought
in a careful assessment of model structures, the particular
perspectives adopted for each analysis and the values used
for the parameters, which is beyond the scope of this com-
mentary. In addition, we haven't attempted to model the
effect of uncertainty on the conclusions. This would
require access to the models, data and software used in
each of the previous three studies. Policy-makers should
review the three papers and make a judgement over which
they believe produces the best estimates of change in cost
and health benefit, identify their willingness to pay for the
proposed health benefits and make their decision in the
context of other logistic, social and political issues.
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